For pediatric brain tumors, especially low grade astrocytoma and ependymoma only limited studies have been published.[16] ErbB TK inhibitors combined with radiotherapy failed to show increase in progression free survival or overall survival in malignant pediatric brain tumors.[10] Canertinib, inhibiting all four ErbB family members, has not yet been investigated in (pre)clinical pediatric brain tumor studies. This evidence concerns the gene EGFR and brain neoplasm.